Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
Theriva Biologics (NYSE American: TOVX) announced its participation in the A.G.P. 2024 Virtual Healthcare Conference. The event is scheduled for May 21, 2024, at 7:30 AM ET. The company's management will provide a corporate update and participate in a fireside chat. Theriva Biologics, a clinical-stage company, focuses on developing therapeutics for cancer and related diseases. The presentation will be available via webcast.
- Theriva Biologics is participating in a high-profile healthcare conference, potentially increasing visibility and investor interest.
- Management will provide a corporate update, which could reveal new developments and strategic initiatives.
- The webcast availability allows broader access for stakeholders and potential investors.
- The announcement lacks specific new data or breakthroughs, which may underwhelm investors looking for significant updates.
- No financial data or clinical trial results were disclosed, leaving gaps in investor insights.
ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in a fireside chat at the A.G.P. 2024 Virtual Healthcare Conference.
A.G.P. 2024 Virtual Healthcare Conference
Format: Fireside Chat
Presentation Date: Tuesday, May 21, 2024
Presentation Time: 7:30 AM ET
Webcast: Click here
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.
For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
Source: Theriva Biologics, Inc.
FAQ
What event is Theriva Biologics (TOVX) participating in?
When is Theriva Biologics presenting at the A.G.P. 2024 Virtual Healthcare Conference?
What type of presentation will Theriva Biologics give at the A.G.P. 2024 Virtual Healthcare Conference?
How can I watch Theriva Biologics' presentation at the A.G.P. 2024 Virtual Healthcare Conference?
What is the focus of Theriva Biologics (TOVX)?
